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Introduction
The intracellular Ras‑regulated Raf/MEK/ERK protein 
kinase signal cascade is a key pathway involved in 
cellular proliferation and survival. A strong correlation 
between deregulation of this pathway and uncontrolled 
cell proliferation has been demonstrated.[1] Selumetinib 
(AZD6244, ARRY‑142886) is a potent, selective, 
uncompetitive inhibitor of MEK ½, developed as 
targeted therapy to treat solid cancers. A favorable 
toxicity, pharmacokinetic, and pharmacodynamic 
profile has been observed in phase I studies and phase 
II studies focusing on melanoma and colorectal cancer 
(CRC).[2‑4] The development of targeted agents requires 
identification and better understanding of positive 
predictive biomarkers of clinical response to these 
agents. Currently, the CT Response Evaluation Criteria 
in Solid Tumors (RECIST) are mostly used to evaluate 
response.[5] These RECIST guidelines are based on the 
sum of one‑dimensional measurements of the greatest 
diameter of the tumor and/or metastases.[5,6] However, 
treatment with targeted therapies is cytostatic rather 
than cytotoxic, and can result in necrosis and cavitation 
without a change in lesion (or tumor) size, leading to 
an underestimation of therapeutic efficacy. Imaging 
techniques able to predict treatment outcome in an early 
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Abstract
Selumetinib (AZD6244, ARRY‑142886) is a potent, selective, uncompetitive inhibitor of MEK 1 / 2, part of the RAF/MEK/ERK 
protein kinase signal cascade, which is responsible for tumor. This pilot study was used to explore if 18F‑fluoro‑l‑thymidine (FLT), a 
thymidine analogue positron emission tomography (PET) tracer and a surrogate marker for proliferation, can be used as an early 
predictor of response for patients with solid cancers treated with Selumetinib. FLT‑PET scans were performed in four patients at 
baseline and after 2 weeks of treatment with Selumetinib. FLT uptake in tumors was analyzed qualitatively and quantitatively by 
measuring standard uptake value (SUV) max in regions of interest (ROI). Results were compared to computed tomography (CT) 
scans (baseline and after 8 weeks), which were evaluated using the response evaluation criteria in solid tumors (RECIST) 1.0 
criteria. One patient with melanoma showed both a qualitative and quantitative decrease in FLT uptake associated with a decrease 
in sum of longest diameter of 12% RECIST on CT evaluation. Another patient who had colorectal carcinoma (CRC) showed a 
significant increase in FLT uptake with initially stable, but eventually progressive disease on CT. The other two patients (one 
with melanoma and one with CRC) showed no significant changes in FLT uptake, whereas CT evaluation showed progressive 
disease. This is the first report describing changes in FLT‑PET in patients receiving Selumetinib. In two patients, changes in FLT 
uptake as early as after 2 weeks of treatment were consistent with CT results after 8 weeks. Biomarkers to predict and evaluate 
treatment the outcome of targeted therapies are highly warranted. These initial results need further investigation.
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phase of treatment are warranted. Molecular imaging 
may enable alternative evaluation procedures for these 
new drugs and enable the early change to an alternative 
therapy if no functional response is indicated. Recently 
the functional imaging technique of positron emission 
tomography (PET) using the radiopharmaceutical 
tracer 18F‑fluorodeoxyglucose (FDG) has been found to 
be a useful method for response monitoring in various 
malignancies.[7‑11] However, FDG is a tracer for glucose 
metabolism, which does not always reflect proliferation 
activity. The PET agent 18F‑fluoro‑l‑thymidine (FLT) has 
been introduced for imaging of cell proliferation. FLT is 
a thymidine analogue, which is retained in proliferating 
cells through the activity of the enzyme thymidine 
kinase‑1, which is expressed during the DNA synthesis 
phase of the cell cycle.[12] FLT‑PET has been applied 
for the assessment of proliferation rate in different 
tumors.[13‑18] In this pilot study, we assessed the effect of 
Selumetinib on tumor cell proliferation in patients with a 
variety of solid tumors by FLT‑PET‑CT and determined 
whether changes in FLT uptake can potentially be used 
as an early predictive biomarker for treatment response.
Materials and Methods
Patients
This single‑institution study was conducted in 
conjunction with Phase I clinical trial of the capsule 
formulation of Selumetinib (NCT00463814) in patients 
with solid tumors.[2] In this study, patients with advanced 
solid cancer refractory to standard therapies or for whom 
no conventional therapies exists were treated with oral 
Selumetinib twice daily in a dose escalation schedule. 
As part of this study protocol, an evaluation CT scan 
was performed after every two cycles (i.e. at 8 weekly 
intervals of treatment with Selumetinib).
Patients participating in the FLT‑PET side study had to 
have at least one tumor deposit of at least 2 cm outside 
the liver and axial skeleton. All patients gave written 
informed consent and both studies were approved by 
the local ethical committee.
FLT‑PET
FLT‑PET scans were performed at baseline and after 
2 weeks of treatment. The scans were performed on an 
integrated PET‑CT scanner (Siemens/Biograph) using 
a static whole body protocol (hips to base of skull) 1 h 
after administration of 250 MBq FLT.
The FLT‑PET images were analyzed both visually for 
any tumor targeting and quantitatively for changes in 
FLT uptake. Quantitative assessment was realized by 
drawing CT‑derived 3D regions of interest (ROI) over 
the tumors, with both a threshold of 50% and 70% of 
the maximum FLT‑activity via an automatic algorithm. 
Standardized uptake values (SUVs) were calculated 
using the concentration of FLT in the volume of interest 
(VOI) as measured by PET, divided by the injected dose 
per kg body weight as a normalization factor.
Evaluation
FLT‑PET scans were analyzed by two nuclear medicine 
physicians. Only lesions outside of the liver and axial 
skeleton, with a diameter of 2 cm or more, which were 
also measured on CT, were evaluated. Based on two 
recent studies by de Langen et al. and Wahl et al., any 
changes in SUVmax greater than 30% were considered 
as significant and medically relevant, independent of 
day‑to‑day variability.[19,20] CT scans were analyzed 
using the RECIST 1.0 guidelines.[6] Quantitative (mean 
SUVmax of measured lesions) FLT‑PET results were 
compared with the results of the radiological evaluation 
with CT‑scan based on RECIST 1.0 criteria.
Results
In four patients, both baseline and follow‑up FLT‑PET‑CTs 
were performed. Two patients had metastasized melanoma 
and two patients had advanced/metastatic CRC. One 
patient with melanoma showed both a qualitative and 
quantitative decrease in FLT uptake, correlating with a 
decrease in sum of diameters of 12% applying RECIST 
to CT evaluation [Figures 1 and 2]. Another patient who 
had CRC showed a significant increase in FLT uptake 
with initially (at 8 weeks) stable disease, but eventually 
progressive disease on CT. The other two patients (one 
with melanoma and one with CRC) showed no significant 
changes in FLT uptake, whereas CT evaluation showed 
progressive disease [Table 1].
Discussion
In the new era of targeted therapies, there is a need 
for early identification of therapy responding and 
non‑responding patients, in order to be able to change 
therapy, thereby working toward personalized medicine. 
Response monitoring for targeted therapies demands 
more specific diagnostic modalities than conventional 
imaging alone. Differentiation between vital tumor 
and fibrosis or necrosis is not possible by using 
morphological features as in RECIST. Furthermore, 
with functional and molecular imaging techniques, one 
could prevent a patient from unnecessarily suffering 
from drug side effects by differentiating responders from 
non‑responders in an early stage of treatment.
As mentioned before, PET with FDG already has an 
established role in monitoring various anti‑cancer 
therapies such as targeted therapies in malignant 
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gastrointestinal stromal tumors.[10] This has led to the 
creation of the recently developed PET Response Criteria 
in Solid Tumors (PERCIST).[20]
Beyond FDG, more specific imaging biomarkers for PET 
have been developed of which a reasonable amount is 
already in clinical stage like 18F‑16α‑17‑fluoroestradiol 
(18F‑FES), 18F‑galacto‑RGD, and 18F‑FLT, which was used 
in this study.[21]
However, PET is not the only imaging modality with 
potential in early response monitoring in clinical 
oncology. Different magnetic resonance imaging 
(MRI) and magnetic resonance spectroscopy (MRS) 
Figure 2: F‑18 FLT PET/CT scan. Transaxial images: (a) Before treatment and (b) after treatment. A female patient with pleural metastases of 
a melanoma, showing decreased FLT uptake in the pleural metastases after treatment with Selumetinib for 2 weeks (Patient No. 1) [Table 1]
a
b
 Figure 1: F‑18 FLT PET/CT scan. Coronal images: (a) Before treatment and (b) after treatment. A female patient with pleural metastases of a 
melanoma, showing decreased FLT uptake in the pleural metastases after treatment with Selumetinib for 2 weeks (Patient No. 1) [Table 1]
a
b
Table 1: Changes in mean SUVmax compared to CT changes according to RECIST after Selumetinib therapy 
in four patients with metastatic melanoma or metastatic colorectal carcinoma














1 Melanoma 3 4.59 1.43 −69 156 138 −12
2 CRC 1 1.81 4.19 +130 77 81 +5
3 Melanoma 5 6.47 5.32 −18 212 257 +21
4 CRC 2 2.39 1.72 −28 215 223 +4*
*Although no significant change was observed in the sum of diameters, a new lesion was found and thus progressive disease according to RECIST 1
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techniques for functional and molecular imaging have 
been developed.
One of them is dynamic contrast‑enhanced MRI 
(DCE‑MRI) in which the kinetics of contrast agent inflow 
into the tumor after intravenous injection of the agent is 
followed.[22] Since tumor angiogenesis is associated with 
an increase in vessel permeability, this can be measured 
using DCE‑MRI techniques.[23] Morgan et al. found that 
in patients treated with an anti‑angiogenic vascular 
endothelial growth factor receptor tyrosine kinase 
inhibitor, there were significantly greater reductions 
in a pharmacokinetic parameter that was related to 
vessel permeability in patients who showed a positive 
response to treatment than in those who had progressive 
disease.[24]
Furthermore, multimodality imaging has potential 
role in clinical response monitoring, whereas PET/CT 
and single‑photon emission computed tomography 
(SPECT) CT are already widely used for the evaluation 
of cancer.[25] However, the major drawback of these 
techniques is that they are combined by software and 
not acquired simultaneously. Recently, Judenhover et al. 
have performed simultaneously FLT‑PET and MRI in 
a mouse model for colon carcinoma. This system was 
able to image three functional imaging techniques, PET, 
functional MRI, and MRS with morphological MRI.[26]
No fully statistically powered human studies on 
FLT‑PET for cancer therapy response monitoring have 
been performed. Nevertheless, a possible beneficial role 
in therapeutic response of various solid tumors with 
different types of therapy have been shown,[27‑29] as well 
as the potential of using quantitative parameters for FLT 
uptake such as SUV.[19]
This is the first report of 18F‑FLT‑PET to assess the 
effect of the MEK inhibitor Selumetinib. In this limited 
study, FLT‑PET‑CT as an early predictor of response 
on Selumetinib is interesting. Further investigation of 
FLT‑PET as a biomarker of early treatment response is 
needed.
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